NFSG
ITRM

Newbridge Financial Services Group’s Iterum Therapeutics ITRM Stock Holding History

Newbridge Financial Services Group’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15
Closed -$15 – 1334
2025
Q2 		$15 Hold
15
– – ﹤0.01% 1304
2025
Q1 		$18 Hold
15
– – ﹤0.01% 1033
2024
Q4 		$27 Buy
+15
New +$24 ﹤0.01% 1125

Other funds holding ITRM

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $317M AUM 17.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Newbridge Financial Services Group's ITRM Position: Q3 2025 in Review

Newbridge Financial Services Group sold out of Iterum Therapeutics (ITRM) in Q3 2025, closing a stake of 15 shares — an estimated $15 sold.

Newbridge Financial Services Group first reported a position in ITRM in Q4 2024 and held it in 3 quarters. The position peaked at $27 in Q4 2024. 24 funds tracked by Wall St. Rank hold ITRM as of Q3 2025.

  • Newbridge Financial Services Group reported no remaining Iterum Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Newbridge Financial Services Group sold 15 Iterum Therapeutics shares in Q3 2025, an estimated $15.
  • Newbridge Financial Services Group first reported a position in Iterum Therapeutics in Q4 2024 and held it in 3 quarters.
  • Newbridge Financial Services Group's Iterum Therapeutics position peaked at $27 in Q4 2024.
  • 24 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2025.

Based on Newbridge Financial Services Group's 13F filing for Q3 2025, filed 13 Nov 2025.